Published for The Lexington Minuteman Aug. 27.
With Lexington’s Hartwell Avenue corridor a haven for technology companies, Harith Rajagopalanit decided it only made sense for him to move his biomedical company, Fractyl Laboratories, there.
“There’s a really vibrant life sciences sector in Lexington, and Hartwell Avenue has a number of different companies,” said Rajagopalan, co-founder and chief executive officer of Fractyl.
Fractyl Laboratories, formerly a Waltham-based company, is working to develop a cure to hyperglycemia or type-2 diabetes. The disease causes the body to not process blood sugars correctly, causing a buildup of sugars in the blood.
Fractyl’s research is focused around a catheter which burns tissue in a specific location of the small intestine, which Rajagopalan believes will prove to be a cure for the disease.
For the rest of this article, click here.